Ownership and insider activity for ACADIA Pharmaceuticals Inc. (ACAD): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis.
Price
| Price | $27.54 |
| Market Cap | $4.7B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-06 | Schneyer Mark C. | M-Exempt | 14,292 | $255K |
| 2026-08-06 | Schneyer Mark C. | S-Sale | 5,000 | $145K |
| 2026-08-05 | Schneyer Mark C. | M-Exempt | 5,849 | $104K |
| 2026-08-05 | Schneyer Mark C. | M-Exempt | 5,849 | $104K |
| 2026-08-06 | Schneyer Mark C. | S-Sale | 9,292 | $273K |
| 2026-08-05 | Schneyer Mark C. | S-Sale | 5,849 | $170K |
| 2026-08-06 | Schneyer Mark C. | M-Exempt | 14,292 | $255K |
| 2026-07-29 | Thompson Elizabeth H.Z. | M-Exempt | 32,272 | |
| 2026-07-29 | Thompson Elizabeth H.Z. | M-Exempt | 32,272 | |
| 2026-07-30 | Thompson Elizabeth H.Z. | S-Sale | 16,508 | $431K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $163.6M | $69.4M | $134.8M | $189.7M | $326.0M | $147.4M | $114.8M | $188.7M | $319.6M | $177.7M |
| Short-term Investments | $365.4M | $271.9M | $338.8M | $507.7M | $305.9M | $373.3M | $302.0M | $250.2M | $436.4M | $642.0M |
| Receivables | $7.1M | $18.4M | $27.8M | $37.9M | $50.3M | $65.3M | $63.1M | $102.3M | $104.7M | $148.2M |
| Inventory | $4.2M | $5.2M | $4.1M | $6.3M | $9.7M | $7.9M | $6.6M | $35.8M | $21.9M | $34.7M |
| Total Current Assets | $547.9M | $373.5M | $526.1M | $760.2M | $717.6M | $617.8M | $507.9M | $616.1M | $938.3M | $1.06B |
| Property, Plant & Equipment | $3.1M | $2.7M | $3.3M | $12.7M | $56.4M | $66.3M | $61.6M | $56.5M | $50.8M | $54.9M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $7.0M | $5.5M | $4.1M | $2.6M | $1.1M | 0 | 0 | $65.5M | $119.8M | $108.9M |
| Total Assets | $561.2M | $384.5M | $540.2M | $783.2M | $782.6M | $700.1M | $587.8M | $749.0M | $1.19B | $1.56B |
| Accounts Payable | $3.9M | $8.8M | $3.2M | $7.2M | $8.5M | $6.9M | $12.7M | $17.5M | $16.2M | $10.9M |
| Short-term Debt | 0 | 0 | 0 | $3.4M | $5.1M | 0 | 0 | $9.4M | 0 | $11.6M |
| Total Current Liabilities | $42.6M | $49.0M | $59.6M | $74.8M | $106.0M | $96.1M | $125.6M | $254.3M | $394.9M | $277.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $42.7M | $49.2M | $61.1M | $84.0M | $155.6M | $159.2M | $187.4M | $317.2M | $455.0M | $336.8M |
| Retained Earnings | -$934.0M | -$1.22B | -$1.47B | -$1.70B | -$1.99B | -$2.15B | -$2.37B | -$2.43B | -$2.20B | -$1.81B |
| Total Equity | $518.4M | $335.3M | $479.1M | $699.1M | $627.0M | $540.9M | $400.4M | $431.8M | $732.8M | $1.23B |
| Total Debt | 0 | 0 | 0 | $9.8M | $49.5M | $64.4M | $62.0M | $57.2M | $52.0M | $52.2M |
| Net Debt | -$529.0M | -$341.3M | -$473.5M | -$687.6M | -$582.4M | -$456.3M | -$354.8M | -$381.7M | -$704.0M | -$767.5M |
| Working Capital | $505.3M | $324.4M | $466.5M | $685.4M | $611.6M | $521.8M | $382.3M | $361.9M | $543.4M | $785.0M |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 3.39 |
Profitability
| Return on Equity | 32.39% |
| Return on Invested Capital | 6.19% |
| Return on Assets | 21.83% |
| Gross Margin | 91.13% |
| Operating Margin | 7.59% |
| Net Margin | 33.42% |
Related companies: ADMA · BLTE · CRNX · DYN · IMVT · LGND · MIRM
Explore sector: Healthcare · Biotechnology
More sections of ACAD: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks